The Gates Foundation’s new AI initiative: attempting to leapfrog global health inequalities?
By Jonathan Shaffer, Arsenii Alenichev, and Marlyn C. Faure,
BMJ Global Health
| 11. 03. 2023
The Bill & Melinda Gates Foundation has long been criticised for championing the trend of socially reductive, ‘magic bullet’ technical ‘solutions’ to the complex, historically shaped, politically conflicted problems at root of global health inequities.1–5 Their August 9th announcement of the launch of a new US$5 million, 48 project funding push6 to launch new ‘artificial intelligence (AI) large language models (LLM) in low-income and middle-income countries to improve the livelihood and well-being of communities globally’ is set to continue this hegemonic global health trend. And, as much as ‘magic bullets’ can solve issues, they, as bullets, are also capable of wounding and causing harm.
There are at least three reasons to believe that the unfettered imposition of these tools into already fragile and fragmented healthcare delivery systems risks doing far more harm than good.
We are not Luddites. New tools of technology, biomedicine, scientific knowledge and population care have often made life better and safer for those with access and control over their use.7 LLMs and AI, however, will not be so equity-advancing despite the Gates Foundation’s overheated...
Related Articles
By Emily Mullin, Wired | 11.14.2023
In a small initial test in people, researchers have shown that a single infusion of a novel gene-editing treatment can reduce cholesterol, the fatty substance that clogs and hardens arteries over time.
The gene-editing treatment aims to permanently lower cholesterol...
By Carissa Wong, Nature | 11.16.2023
In a world first, the UK medicines regulator has approved a therapy that uses the CRISPR–Cas9 gene-editing tool as a treatment. The decision marks another high point for a biotechnology that has been lauded as revolutionary in the decade since...
By Emily Mullin, Wired | 11.16.2023
The first medical treatment that uses Crispr gene editing was authorized Thursday by the United Kingdom.
The one-time therapy, which will be sold under the brand name Casgevy, is for patients with sickle cell disease and a related blood disorder...
By Alexis Heng, UCA News | 11.13.2023
In recent years, Singapore has increasingly leveraged new reproductive technologies to overcome the country's rapidly aging demographics and dismal fertility rate, which hit a new low in 2022.
Hence, it would be timely for Singapore’s Bioethics Advisory Committee (BAC) to...